Dyadic International, Inc. (NASDAQ:DYAI) Short Interest Update

Dyadic International, Inc. (NASDAQ:DYAI) was the recipient of a large decrease in short interest in the month of February. As of February 28th, there was short interest totalling 96,600 shares, a decrease of 19.9% from the February 13th total of 120,600 shares. Currently, 0.5% of the company’s stock are short sold. Based on an average daily volume of 90,700 shares, the short-interest ratio is presently 1.1 days.

Dyadic International Stock Down 1.4 %

DYAI stock traded down $0.02 during trading hours on Tuesday, reaching $1.38. 296,590 shares of the stock were exchanged, compared to its average volume of 68,522. The firm’s 50-day moving average is $1.51 and its 200-day moving average is $1.42. Dyadic International has a 12 month low of $0.93 and a 12 month high of $2.67. The company has a market cap of $40.83 million, a price-to-earnings ratio of -6.00 and a beta of 0.95. The company has a debt-to-equity ratio of 1.54, a current ratio of 5.15 and a quick ratio of 5.15.

Institutional Trading of Dyadic International

Institutional investors have recently made changes to their positions in the business. Truist Financial Corp acquired a new stake in Dyadic International in the 4th quarter valued at $428,000. Inlet Private Wealth LLC bought a new position in shares of Dyadic International in the 4th quarter valued at about $52,000. Bank of America Corp DE increased its position in shares of Dyadic International by 16,146.7% in the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after acquiring an additional 26,965 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of Dyadic International in the fourth quarter valued at about $45,000. Finally, Millennium Management LLC bought a new stake in Dyadic International during the fourth quarter worth about $28,000. Institutional investors own 27.95% of the company’s stock.

Dyadic International Company Profile

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.